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Abstract
Background: After the approval of pazopanib for the treatment of soft tissue sarcoma (STS), pneumothorax
was reported as an unexpected adverse event during pazopanib treatment. The incidence and risk factors
of pneumothorax during pazopanib treatment for STSs have not been established yet.
Methods: We retrospectively reviewed the cases of all of the STS patients treated with pazopanib between
November 2012 and December 2014 at our institute and evaluated the prevalence, incidence, treatment
details and risk factors for pneumothorax in the STS patients during pazopanib treatment.
Results: A total of 58 patients were enrolled; 45 of them had lung and/or pleural lesions at the start of pazopanib
treatment. During the median follow-up time of 219 days (range 23–659), 13 pneumothorax events occurred in six
patients; the prevalence and incidence of pneumothorax were 10.3 % and 0.56 per treatment-year, respectively. The
median onset of pneumothorax was day 115 (range 6–311). No patients died of pneumothorax, but pazopanib was
interrupted in 10 events and chest drainage was performed in eight events. Pazopanib continuation or restart after
the recovery from pneumothorax was conducted after 9 of the 13 events. The median progression-free survival of
patients with and without pneumothorax events were 144 and 128 days (p = 0.89) and the median overall survival
periods were 293 and 285 days (p = 0.69), respectively. By logistic regression analyses, the maximum diameter of the
lung metastases≥ 30 mm (OR 13.3, 95 % CI 1.1–155.4, p = 0.039) and a history of pneumothorax before the pazopanib
induction (OR 16.6, 95 % CI 1.1–256.1, p = 0.045) were significantly predictive of pneumothorax.
Conclusions: In our retrospective analysis, pneumothorax was observed in 10.3 % of 58 STS patients during pazopanib
treatment. The diameter of the lung metastases and a history of pneumothorax could be useful for evaluating the risk
of pneumothorax in pazopanib treatment.
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Background
Soft tissue sarcomas (STSs) are heterogeneous malignant
diseases, originating from mesenchymal tissues all over
the body. Approximately 30 % of all STS patients have
some metastatic lesions, and the prognoses of metastatic
STS patients are still poor [1–3]. There have been some
case reports of pneumothorax as a complication in STS
patients with lung metastases; due to the rarity of the
event, however, information about the prevalence and
the risk factors of pneumothorax in STS patients has
been limited [4].
In 2012, pazopanib, a multitarget tyrosine kinase in-
hibitor, was approved for the treatment of STS patients
based on the evidence obtained in a phase 3 clinical trial,
in which pazopanib was shown to improve the progno-
ses of advanced STS patients [4]. However, throughout
the more than 2 years after pazopanib’s approval,
pneumothorax has been reported as an unexpected ad-
verse event in STS patients [5, 6]. Though the relation
between pneumothorax and pazopanib treatment is not
clear, once pneumothorax occurs, in most cases pazopa-
nib treatment would have to be interrupted. For the safe
management of pazopanib treatment, it is necessary to
evaluate the prevalence, the incidence and the risk fac-
tors for pneumothorax in STS patients during pazopanib
treatment. Here we investigated the details of pneumo-
thorax events observed in STS patients during pazopa-
nib treatment.
Methods
This study was approved by the ethics committee of Can-
cer Institute Hospital of Japanese Foundation for Cancer
Research. After the approval of the institutional review
board, we retrospectively reviewed the medical records of
STS patients treated with pazopanib at our institute be-
tween November 2012 and December 2014. We deter-
mined the prevalence, the incidence, the severity and the
managements of pneumothorax during these patients’
pazopanib treatment. The prevalence of pneumothorax
was calculated as the percentage of patients suffering from
pneumothorax. The incidence of pneumothorax was cal-
culated as the number of pneumothorax episodes per
treatment-year. The severities of pneumothorax events
were evaluated by grading based on the U.S. National
Center Institute Common Terminology Criteria for
Adverse Events (CTCAE version 4.0).
We also reviewed the baseline characteristics of all of
the STS patients enrolled in the study and evaluated the
clinical risk factors of pneumothorax by comparing the
characteristics of the patients with and without pneumo-
thorax events. We performed univariate and the multi-
variable analyses to evaluate the association between
each risk factor and pneumothorax using Fisher’s extract
test and a logistic regression test, respectively.


























Synovial sarcoma 9 16
Liposarcoma 9 16
Other histologies 27 46




Lung lesions present 41 71
Pleural lesions present 23 40




> 10 13 22
Maximum diameter of lung lesions
< 10 mm 2 3
10–20 mm 11 19
20–30 mm 7 12
30–50 mm 8 14
> 50 mm 13 22
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For the evaluation of prognoses, the progression-free
survival (PFS) and the overall survival (OS) from the
date of pazopanib induction were estimated by the
Kaplan-Meier method. The PFS and the OS of the
patients with and without pneumothorax events were
compared by the log-rank test.
The patients’ objective responses were also evaluated
and compared. The objective response and the disease
progression were defined based on the Response Evalu-
ation Criteria in Solid Tumors (RECIST) version 1.1. In-
dependent of the objective response, cavitations of lung
lesions during pazopanib treatment were also evaluated.
In all analyses, the p-values were two-sided and con-
sidered significant when <0.05.
Results
A total of 58 STS patients had been treated with pazopa-
nib at our institute between November 2012 and
December 2014, and the median follow-up time from
the start of pazopanib treatment was 219 days (range
23–659 days). At the time of our analyses, 43 patients
were certified as showing disease progression and 30
patients had died due to their STS.
The patients’ characteristics at baseline are shown in
Table 1. In Japan, pazopanib is also approved for liposar-
coma treatment, and we thus included nine liposarcoma
patients in the study. Lung and/or pleural lesions were
present at baseline in 45 patients (78 %); lung lesions
were present in 41 (71 %) patients, and pleural lesions
were present in 23 (40 %) patients. Twenty (34 %) pa-
tients had smoking histories; details of smoking index
(the number of cigarette-years) were as follows; median
238, range (64–1170), and smoking index was 400 or
more in 6 patients.
The prevalence, incidence and management of
pneumothorax
Throughout the follow-up period, 13 pneumothorax
events were observed in six of the 58 STS patients en-
rolled in the analysis; the prevalence of pneumothorax
was 10.3 %. The median pazopanib treatment period
was 115 days (range 5–659 days), and the incidence of
pneumothorax was 0.56 per treatment-year. The median
Table 2 Details of pneumothorax events during pazopanib treatment
Patient characteristics Clinical status at the occurrence of pneumothorax
No. Age Pathological diagnosis Treatment day Grade Bilateral Chest drainage
1 60’s Undifferentiated sarcoma, NOS 115 1 No No
2 40’s Carcinosarcoma 12 3 No Yes
3 20’s Undifferentiated sarcoma, NOS 6 3 No Yes
25 3 No Yes
61 3 Yes Yes
129 2 No Yes
144 3 No Yes
4 20’s Synovial sarcoma 55 3 No Yes
95 3 Yes Yes
5 50’s Synovial sarcoma 145 1 No No
174 2 No No
282 1 No No
6 30’s Synovial sarcoma 311 2 No No
Fig. 1 Radiographs of two bilateral pneumothorax events. a A bilateral pneumothorax in Patient 3 on treatment day 61. In this patient,
cavitations of lung lesions were observed. b Bilateral pneumothorax events of Patient 4 on treatment day 95. In the CT scan, progression
of lung lesions was also observed
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onset of pneumothorax events was at 115 days of pazo-
panib treatment. All patients with pneumothorax events
had lung and/or pleural lesions at the start of pazopanib.
The details of pneumothorax events are shown in
Table 2. Based on the CTCAE, 7 of the 13 pneumo-
thorax events were evaluated as grade 3, and in two
events pneumothorax occurred bilaterally (Fig. 1). Re-
currences of pneumothorax events were observed in
three patients. In Patient 3, a 27-year-old male with un-
differentiated sarcoma, not otherwise specified (NOS),
pneumothorax events occurred five times during pazo-
panib treatment. No patients died of pneumothorax, but
pazopanib treatment was interrupted in 10 events and
the chest drainage was performed in eight events. Pazo-
panib continuation or restart after the recovery from
pneumothorax was conducted after nine events. The
clinical courses of the six patients with pneumothorax
are summarized in Fig. 2.
Risk factors of pneumothorax
In our univariate analysis of baseline characteristics of
the STS patients treated with pazopanib, the patho-
logical diagnosis of synovial sarcoma, the presence of
lung lesions with ≥ 30 mm dia. and the presence of his-
tories of pneumothorax were significant (Table 3). Of
these, the multivariable analysis revealed that the
maximum diameter of the lung metastases ≥ 30 mm
(adjusted odds ratio [OR] = 13.3, 95 % confidence inter-
val [CI] = 1.1–155.4, p = 0.039) and the presence of a his-
tory of pneumothorax before the pazopanib induction
Fig. 2 Clinical courses of each of the six patients who had pneumothorax episodes during pazopanib treatment
Fig. 3 Prognoses of the patients with or without pneumothorax. Prognoses of the patients with or without pneumothorax: overall survival (OS)
and progression-free survival (PFS)
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(adjusted OR 16.6, 95 % CI 1.1–256.1, p = 0.045) were
also significantly predictive of pneumothorax (Table 4).
Prognoses and responses to pazopanib in STS patients
with and without pneumothorax
The median PFS and OS of all STS patients treated with
pazopanib were 130 days (95 % CI 112–148) and
285 days (95 % CI 256–313). The comparison of progno-
ses between the patients with and without pneumo-
thorax by log-rank test showed that the median PFS of
the patients with and without pneumothorax were 144
and 128 days (p = 0.89) and the median OS values were
293 and 285 days (p = 0.69), respectively (Fig. 3). There
were no significant differences in PFS or OS due to the
presence of pneumothorax events. Prognostic factors
other than the presence of pneumothorax were also
evaluated by the log-rank test, but there were no statisti-
cally significant factors (Table 5).
As for the objective responses, a partial response (PR)
was observed in 5 of the 58 STS patients (the response
rate was 8.6 %); there were no PRs in the patients with
pneumothorax (based on the RECIST criteria). Cavita-
tions of lung lesions were observed in four patients, and
two of them had pneumothorax during pazopanib treat-
ment (Patient No. 1 and No. 3).
Discussion
The lung is the major organ in which STS metastases
are most often observed; 22 % of all STS patients have
lung metastases [7]. Though there have been many case
reports of STS patients with pneumothorax, the preva-
lence and the risk factors of pneumothorax in STS
patients have not yet been established.
Hoag et al. reviewed case reports of pneumothorax in
STS patients and estimated that the prevalence of
pneumothorax in STS patients is 1.9 % [8]. this preva-
lence is higher than those of patients with primary lung
cancers, which was estimated as 0.32 % in Lai’s retro-
spective analysis [9].
During pazopanib treatment, the prevalence of
pneumothorax in STS patients might be higher. In
2014, we preliminarily reported the prevalence of
pneumothorax in 32 STS patients treated by pazopa-
nib as 9.4 % [5], and in the present study the preva-
lence of pneumothorax among 58 STS patients was
10.5 %. Similar to our results, Verschoor et al. re-
ported case series of pneumothorax in STS patients
treated by pazopanib; 6 of 43 patients experienced
pneumothorax in their study (14.0 %) [6]. In our
present study, the prevalence of pneumothorax was
even higher than those in prospective clinical trials
or multicenter analyses of pazopanib-treated STS
patients. In the Palette study, a multicenter phase III
trial of pazopanib treatment for STS patients, the
prevalence of pneumothorax was 3 % (8 of 246
patients) [4]. In the post-marketing surveillance of
pazopanib in Japan, pneumothorax was observed in
Table 3 Univariate analyses of risk factors of pneumothorax in
STS patients during pazopanib treatment
Pneumothorax Present (n = 6) Absent (n = 52)
Variants No. % No. % p-value
Gender
Male 5 83 29 56 0.097
Female 1 17 23 44
Pathological diagnosis
Synovial sarcoma 3 50 6 12 0.042
Others 3 50 46 88
Hypertension
Present 1 17 9 17 1.00
Absent 5 83 43 83
Smoking history
Present 3 50 17 33 0.41
Absent 3 50 35 67
Smoking index≥ 400
Present 2 33 4 8 0.11
Absent 4 67 48 92
Lung lesion
Present 6 100 35 67 0.17
Absent 0 0 17 33
Pleural lesion
Present 4 67 19 37 0.20
Absent 2 33 33 63
No. of lung lesions
0–1 0 0 29 56 0.072
2 or more 6 100 23 44
Maximum dia. of lung lesions
≥ 30 mm 5 83 16 31 0.02
< 30 mm 1 17 36 69
History of lung surgery
Present 2 33 19 37 1.00
Absent 4 67 33 63
History of pneumothorax
Present 2 33 2 4 0.049
Absent 4 67 50 96
Table 4 Multivariable analyses of risk factors of pneumothorax
in STS patients during pazopanib treatment
Variate Adjusted Odds ratio 95 % CI p-value
Maximum dia. of lung
lesions≥ 30 mm
13.3 1.1–155.4 0.039
History of pneumothorax 16.6 1.1–256.1 0.045
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23 of 539 patients who received pazopanib (4.3 %),
and 12 patients (2.2 %) were diagnosed as grade 3 or
more [10].
At our institute, pneumothorax events occurred soon
after the approval of pazopanib, and since then chest
radiographs have been performed once or twice monthly
during pazopanib treatment in clinical practice. This fre-
quent evaluation by chest radiographs helps identify
low-grade pneumothorax without clinically relevant
symptoms, and it might be the reason for the high
prevalence of pneumothorax in our present analysis; in
fact, if we exclude the patients with only low-grade
pneumothorax (Patient Nos. 1, 5 and 6), the prevalence
of severe pneumothorax at our institute was 3 of 58
patients (5.2 %). This result is similar to the prevalence
of pneumothorax in the Palette study.
Pazopanib is considered an antiangiogenic agent since
it targets the vascular endothelial growth factor receptor
(VEGFR) [4]. Antiangiogenic agents are known to cause
cavitations of lung lesions [11, 12]. It has been suggested
that tumor cavitations during or after chemotherapy
might be signs of the clinical response, but also that they
could be risk factors for pneumothorax [13]. Our
present population included patients in whom cavita-
tions of lung lesions developed during pazopanib
treatment, especially among the patients with
pneumothorax events. In STS patients, however, cavi-
tations of lung lesions have also occurred during che-
motherapies using cytotoxic agents, and it is thought
that the necrosis of pulmonary or pleural lesions in
response to chemotherapy by cytotoxic agents could
be responsible for pneumothorax [8, 14]. Moreover, in
the prospective clinical trials of pazopanib treatment
for malignancies other than STS, such as renal cell
carcinomas and ovarian cancers, pneumothorax was
more rarely reported as an adverse event [15, 16]. As
for STS patients, the nature of the disease could be
more closely related to risk factors of pneumothorax
than are the treatment drugs.
In our current analysis, the clinical features of max-
imum lesion size and number of lung lesions were sig-
nificant predictors of pneumothorax in the multivariable
analysis. However, our analysis was retrospective study,
and, due to the small sample size and few numbers of
events, the range of adjusted odd ratios were broad
(Table 4). These are the limitations of our study, and the
re-analyses of bigger sample size, prospective cohorts
will be necessary for the certification of risk factors of
pneumothorax. In other studies, good performance
status and a normal hemoglobin level were suggested
to be advantageous for long-term outcomes, and older
age was suggested to be associated with liver toxicity
[17, 18]. By updating STS patients’ clinical informa-
tion and analyses, it could be possible to estimate the
risk of pneumothorax more precisely in the future.
Conclusion
Pneumothorax was observed in 10.3 % of 58 STS pa-
tients during pazopanib treatment. By the multivariable
analyses, the diameter of the lung metastases and a his-
tory of pneumothorax could be useful for evaluating the
risk of pneumothorax in pazopanib treatment.
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